Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

New HIV two-drug regimen launched in the UK

A new drug for the treatment of HIV infection in adults has been launched in the UK. 

A new drug for the treatment of HIV infection in adults has been launched in the UK.   Dolutegravir/rilpivirine is licenced for patients who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.  It is a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Therapeutics, Division of Janssen Products LP). A key driver for the 2-drug regimen is that people with HIV are now living into old age thanks to the advances of the

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy